Phaseline

Companies › Agomab Spain S.L.U.

Agomab Spain S.L.U.: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ontunisertib–Phase 2Fibrostenotic Crohn's DiseaseDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07672574OntunisertibPhase 1Fibrostenotic Crohn's DiseaseImmunologySep 2026
NCT07683325OntunisertibPhase 2Fibrostenotic Crohn's DiseaseImmunologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Calixis Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Qifeng Zhang Topadur Pharma Leadingtac Pharmaceutical (Shaoxing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.